Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SX-682 with Bintrafusp Alfa and CV301 in Advanced Solid Tumors
NCT04574583Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in solid tumor, triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Nov 2020; status: completed.
02
Drugs
SX-682
03
Conditions
solid tumortriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04574583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574583.